2020.09.08
I-Mab today announced its participation in the following conferences in September, including Cantor Fitzgerald Virtual Global Healthcare Conference 2020, Jefferies Virtual Asia Forum, ICBCI Virtual ADR New Economy Conference, 2020 Huatai USA Autumn Virtual China Conference, and Morgan Stanley Virtua...
2020.09.04
I-Mab today announced that it has entered into definitive subscription agreements with a consortium of institutional investors to raise approximately US$418 million through a private placement.
2020.09.04
AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two p...
2020.08.31
I-Mab today announced financial results for the six months ended June 30, 2020 and provided an overview of recent highlights and upcoming milestones.
2020.08.17
I-Mab today announced that the first patient has been dosed with plonmarlimab (TJM2) in a Phase 1b study to evaluate its use in treating patients with rheumatoid arthritis in China.
2020.08.06
Conference Call Scheduled for August 31 at 8:00 a.m. ET with Pre-Registration Required.
2020.08.04
I-Mab today announced that the China National Medical Products Administration (NMPA) has accepted its pivotal trial application for eftansomatropin (also known as TJ101) as a weekly treatment for growth hormone deficiency in pediatric patients (PGHD).
2020.07.28
I-Mab today announced the appointment of Mr. Ivan Yifei Zhu as its Chief Commercial Officer, effective August 10, 2020. Mr. Zhu will report directly to Dr. Jingwu Zang, Founder, Honorary Chairman and Director of I-Mab. In this role, Mr. Zhu will focus on building and developing I-Mab’s commercializa...
2020.07.15
I-Mab announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to US$20 million of its ordinary shares in the form of American depositary shares.
2020.06.12
I-Mab and ABL Bio will be presenting preclinical data for joint bispecific antibody program at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22-24, 2020. The preclinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-M...